Analyst consensus rating
Silence Therapeutics Analyst Rating: Buy
Direct answer
Silence Therapeutics's consensus rating is Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $33.50.
Forecast evidence checked October 21, 2026.
Get free Silence Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $19.64
- Average price target
- $33.50
- High price target
- $75.00
- Low price target
- $19.00
- Low target gap
- -3.2%
- Target upside
- +70.6%
- High target gap
- +282%
- Target range width
- 285.2%
- Consensus rating
- Buy
- Analysts
- 4
- Evidence date
- October 21, 2026
- Valid through
- October 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Silence Therapeutics?
Silence Therapeutics has a verified Buy consensus. The same dataset has an average price target of $33.50.
How far are Silence Therapeutics's low and high targets from the recorded price?
The low target implies -3.2%, while the high target implies +282%.
How many analysts are included in Silence Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Silence Therapeutics's target upside or downside calculated?
The average target of $33.50 is divided by the recorded price of $19.64, then one is subtracted to produce +70.6%. This does not guarantee a future return.
When was Silence Therapeutics's analyst forecast verified?
The data was verified on 2026-10-21. The dataset is valid through 2026-10-28.